stem-cell-congress-cardiology-2018-keynote

9 / 9

alliedacademies
CARDIOLOGY AND CARDIOVASCULAR MEDICINE
STEM CELLS AND REGENERATIVE MEDICINE
&
International Conference on
International Conference on
J u n e 1 8 - 1 9 , 2 0 1 8 | O s a k a , J a p a n
Biomedical Research | Volume 29
Page 31
Note:
Joint Event on
Restenosis and late thrombus formation are the most challenges
to stent intervention. Drug release from a drug eluting stent (DES)
is a very effective solution for suppressing restenosis, but increasing
late thrombus rate is even dangerous because of over 50% of death
rate. Recently, a stent consists of metal stent/titanium oxide film/
drug eluting coating (mixture layer of the biodegradable polymer PLGA
and rapamycin) produced by author’s lab. has been applied in clinic
in China. The two surface coating treated stent played multifunction
anti-restenosis and thrombus resistance after stent intervention. Clinic
trial date showed that restenosis rate of the developed stent was as
lower as 1.1%, and no late thrombus, however the late thombus rate
of comparing stent was 2.1% during one year and after four years the
thrombus formed patients in comparing group were increased to 3.9%,
and 3% patients in comparing group were die due to the late thrombus.
However no late thrombus and no cardiac death were reported for the
multilayer stent group. The stent intervention have applied on about
70,000 patients, the follow up investigation for one year with 2,000
patients revealed that the late thrombus,cardiac death rate, TLF, and
MACE are 0.1%, 0.1%, 0.2%, 0.65% respectively, a order of magnitude
lower than other commercial proposed a novel conception:
“Time sequence functional stent”, the stent whichpossess the functions
that can always match the interaction of the stent with the biological
environment of the host in the intervention time sequences can has
the ability to suppress the complications in the clinic practice. This
presentation discussed in detail about how the developed multilayer
stent match the conception of time sequence functional stent, and the
further development tendency of a stent according to the conception.
Biography
Nan Huang has been the Chairman of the Interna-
tional Committee of Surfaces and the Interfaces
of Biomaterials, and the Fellow of the Internation-
al Union of Societies for Biomaterials Science &
Engineering since 2007 and 2008 respectively. He
was the Chairman or Co-Chair of 5 international
conferences. He published over 400 papers on
the international journals, 50 pieces of inventions,
and presented over 30 times on international con-
ferences as plenary speaker or keynote speaker.
And he is an inventor of a stent with novel multi-
function applied in clinic. His team is developing a
new type of ventricular pump and thrombus filter
cooperating with companies.
TIME SEQUENCE FUNCTIONAL
STENT: A NOVEL CONCEPTION
AND CLINIC PRACTICE
Nan Huang
Southwest Jiaotong University, China
Nan Huang, Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C2-004